B. Riley initiated coverage of Oncology Institute (TOI) with a Buy rating and $6 price target The firm says Oncology Institute is one of the largest oncology specialty value-based healthcare service providers. The company’s recent debt facility amendment removed a key financial overhang on the shares, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOI:
- Oncology Institute names Kristin England chief administrative officer
- Oncology Institute to be exclusive oncology provider for SilverSummit Healthplan
- Oncology Institute files $50M common stock offering
- Oncology Institute management to meet virtually with B. Riley
- Oncology Institute to join Russell 2000, Russell 3000 indexes